Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

February 22, 2027

Study Completion Date

February 22, 2027

Conditions
Cancer
Interventions
DRUG

Osimertinib

Osimertinib (dose range of 40 mg to 240 mg orally, once daily)

Trial Locations (27)

333

Research Site, Taoyuan District

704

Research Site, Tainan City

736

Research Site, Tainan City

5505

Research Site, Seoul

10408

Research Site, Goyang-si

10450

Research Site, George Town

13620

Research Site, Seongnam-si

25100

Research Site, Kuantan

28644

Research Site, Cheongju-si

40705

Research Site, Taichung

44033

Research Site, Donggu

81100

Research Site, Johor Bahru

83301

Research Site, Kaohsiung City

93586

Research Site, Kuching

94805

Research Site, Villejuif

100142

Research Site, Beijing

112201

Research Site, Taipei

200433

Research Site, Shanghai

225001

Research Site, Yangzhou

400042

Research Site, Chongqing

450008

Research Site, Zhengzhou

70-419

Research Site, Szczecin

03080

Research Site, Seoul

03722

Research Site, Seoul

06351

Research Site, Seoul

06591

Research Site, Seoul

NG5 1PB

Research Site, Nottingham

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY